IGF1R
IGF1R (insulin-Like growth factor 1 receptor) is a receptor tyrosine kinase that bind to insulin-like growth factor 1 with high affinity. It plays a vital role in in cell growth, cell survival and malignant transformation etc.
Products Related to IGF1R(34)
- GC12273GSK1838705ACAS: 1116235-97-2Purity: >99.00%
GSK1838705A is a small-molecule kinase inhibitor that targets Insulin-like Growth Factor 1 Receptor (IGF-1R) and the insulin receptor, with IC₅₀ values of 2.0nM and 1.6nM, respectively.
- GC15749LinsitinibCAS: 867160-71-2Purity: >98.00%
Linsitinib is a potent, selective, and orally bioavailable dual IGF-1R/IR kinase inhibitor, with the IC 50 values of 0.035μM, and 0.075μM, respectively.
- GC16821TAE226(NVP-TAE226)CAS: 761437-28-9Purity: >98.00%
TAE226(NVP-TAE226) is a potent ATP-competitive inhibitor that inhibits a variety of tyrosine protein kinases, especially FAK and IGF-IR kinases, with IC 50 values of 5.5nM and 140nM, respectively.
- GC31706Ginsenoside Rg5CAS: 186763-78-0Purity: >98.00%
A ginsenoside with diverse biological activities
- GC34287AZ7550 hydrochlorideCAS: 2309762-40-9Purity: >98%
AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
- GC36311Indirubin Derivative E804CAS: 854171-35-0Purity: >99.50%
Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC50 of 0.65 μM for IGF1R.
- GC44474NVP-AEW541 (hydrochloride)CAS: 2320261-63-8Purity: >98.00%
Insulin-like growth factor 1 receptor (IGF-1R) is a receptor tyrosine kinase whose activation leads to angiogenesis as well as cell proliferation, survival, transformation, and metastasis.
- GC45789Ceritinib-d7CAS: 1632484-77-5Purity: >99.00%
An internal standard for the quantification of ceritinib
- GC61111NBI-31772 hydratePurity: >98.00%
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs).
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC13697 | AG-1024 | 65678-07-1 | >98.50% | |
AG-1024 is a reversible, competitive and selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC 50 value of 7μM. AG-1024 can inhibit the phosphorylation of insulin receptor (IR) with an IC 50 value of 57μM. | ||||
| GC16991 | PQ 401 | 196868-63-0 | >99.50% | |
IGF1R inhibitor,potent and cell-permeable | ||||
| GC12273 | GSK1838705A | 1116235-97-2 | >99.00% | |
GSK1838705A is a small-molecule kinase inhibitor that targets Insulin-like Growth Factor 1 Receptor (IGF-1R) and the insulin receptor, with IC₅₀ values of 2.0nM and 1.6nM, respectively. | ||||
| GC12712 | NT157 | 1384426-12-3 | >98% | |
NT157 is a selective inhibitor of insulin receptor substrate-1/-2 (IRS-1/2). | ||||
| GC12963 | NVP-AEW541 | 475489-16-8 | >98.50% | |
IGF-IR inhibitor, novel, potent and selective | ||||
| GC13102 | XL228 | 898280-07-4 | >99.00% | |
A tyrosine kinase inhibitor | ||||
| GC14189 | AZD-3463 | 1356962-20-3 | >99.50% | |
ALK/IGF1R inhibitor | ||||
| GC14552 | LDK378 | 1032900-25-6 | >99.50% | |
LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. | ||||
| GC15749 | Linsitinib | 867160-71-2 | >98.00% | |
Linsitinib is a potent, selective, and orally bioavailable dual IGF-1R/IR kinase inhibitor, with the IC 50 values of 0.035μM, and 0.075μM, respectively. | ||||
| GC16712 | BMS-754807 | 1001350-96-4 | >98.00% | |
IGF-1R/InsR inhibitor,potent and selective | ||||
| GC16821 | TAE226(NVP-TAE226) | 761437-28-9 | >98.00% | |
TAE226(NVP-TAE226) is a potent ATP-competitive inhibitor that inhibits a variety of tyrosine protein kinases, especially FAK and IGF-IR kinases, with IC 50 values of 5.5nM and 140nM, respectively. | ||||
| GC17045 | AXL1717 | 477-47-4 | >99.50% | |
AXL1717 is an orally active and highly selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC 50 value of 1nM. | ||||
| GC17452 | LDK378 dihydrochloride | 1380575-43-8 | >99.50% | |
| GC17612 | GSK1904529A | 1089283-49-7 | >99.00% | |
Selective IGF-1R/IR inhibitor | ||||
| GC17773 | BMS-536924 | 468740-43-4 | >98.50% | |
IR/IGF-1R inhibitor | ||||
| GC25881 | S961 | 1083433-49-1 | >98% | |
S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells. | ||||
| GC31706 | Ginsenoside Rg5 | 186763-78-0 | >98.00% | |
A ginsenoside with diverse biological activities | ||||
| GC33072 | AZ7550 | 1421373-99-0 | >98% | |
AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. | ||||
| GC34287 | AZ7550 hydrochloride | 2309762-40-9 | >98% | |
AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. | ||||
| GC34414 | AZ7550 Mesylate (AZ7550 trimesylate salt) | - | >98% | |
| GC36311 | Indirubin Derivative E804 | 854171-35-0 | >99.50% | |
Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC50 of 0.65 μM for IGF1R. | ||||
| GC44474 | NVP-AEW541 (hydrochloride) | 2320261-63-8 | >98.00% | |
Insulin-like growth factor 1 receptor (IGF-1R) is a receptor tyrosine kinase whose activation leads to angiogenesis as well as cell proliferation, survival, transformation, and metastasis. | ||||
| GC45789 | Ceritinib-d7 | 1632484-77-5 | >99.00% | |
An internal standard for the quantification of ceritinib | ||||
| GC61111 | NBI-31772 hydrate | - | >98.00% | |
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). | ||||
